Richard H. Bagger net worth and biography

Richard Bagger Biography and Net Worth

Director of Tonix Pharmaceuticals

Richard Bagger became a Director in June 2020. Mr. Bagger has been a Partner and Executive Director of Christie 55 Solutions, LLC, a New Jersey based consulting firm, since January 2020. Mr. Bagger has also been an Adjunct Faculty member at the Rutgers University Eagleton Institute since 2018. From 2012 through 2019, Mr. Bagger was Executive Vice President of Corporate Affairs and Market Access for Celgene Corporation (NASDAQ: CELG), a global biopharmaceutical company, as well as a member of its Executive Committee. From 1993 to 2010, Mr. Bagger held roles of increasing responsibility with Pfizer Inc. (NYSE: PFE), a global pharmaceutical company, and served as Senior Vice President, Worldwide Public Affairs and Policy, from 2006 to 2009. Prior to joining Pfizer, Mr. Bagger was Assistant General Counsel of Blue Cross and Blue Shield of New Jersey, a health insurer, and practiced law with the law firm of McCarter & English. Mr. Bagger served as Board Chair of the National Pharmaceutical Council for 2019 and is a member of the Board of Directors of the U.S. Chamber of Commerce. He is also on the advisory board for the Lerner Center for the Study of Pharmaceutical Management Issues at Rutgers University Business School.

Mr. Bagger received an AB degree from Princeton University’s Woodrow Wilson School of Public and International Affairs and a JD degree from Rutgers University Law School. Mr. Bagger’s extensive healthcare and public policy experience were instrumental in his selection as a member of the Board.

What is Richard H. Bagger's net worth?: The estimated net worth of Richard H. Bagger is at least $13.64 thousand as of August 20th, 2026. Bagger owns 1,000 shares of Tonix Pharmaceuticals stock worth more than $13,635 as of August 25th. This net worth approximation does not reflect any other investments that Bagger may own. Learn More about Richard H. Bagger's net worth.
How do I contact Richard H. Bagger?: The corporate mailing address for Bagger and other Tonix Pharmaceuticals executives is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. Tonix Pharmaceuticals can also be reached via phone at (862) 799-8599 and via email at [email protected]. Learn More on Richard H. Bagger's contact information.
Has Richard H. Bagger been buying or selling shares of Tonix Pharmaceuticals?: Over the course of the past ninety days, Richard H. Bagger has bought $12,600.00 in shares of Tonix Pharmaceuticals stock. Most recently, on Thursday, August 20th, Richard H. Bagger bought 1,000 shares of Tonix Pharmaceuticals stock. The stock was acquired at an average cost of $12.60 per share, with a total value of $12,600.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company's stock, valued at $12,600. Learn More on Richard H. Bagger's trading history.
Who are Tonix Pharmaceuticals' active insiders?: Tonix Pharmaceuticals' insider roster includes Richard Bagger (Director), Daniel Goodman (Director), Seth Lederman (CEO), Richard Stillwell (Director), and Carolyn Taylor (Director). Learn More on Tonix Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Tonix Pharmaceuticals?: In the last year, Tonix Pharmaceuticals insiders bought shares 5 times. They purchased a total of 27,415 shares worth more than $368,078.25. The most recent insider tranaction occured on August, 20th when Director Richard H Bagger bought 1,000 shares worth more than $12,600.00. Insiders at Tonix Pharmaceuticals own 2.0% of the company. Learn More about insider trades at Tonix Pharmaceuticals.
Information on this page was last updated on 8/20/2026.

Richard H. Bagger Insider Trading History at Tonix Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/20/2026	Buy	1,000	$12.60	$12,600.00	1,000

Richard H. Bagger Buying and Selling Activity at Tonix Pharmaceuticals

Tonix Pharmaceuticals Company Overview

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Today's Range

Now: $13.51

$12.50

$13.95

50 Day Range

MA: $11.85

$9.51

$13.22

2 Week Range

Now: $13.51

$9.40

$34.89

Volume

713,285 shs

Average Volume

459,993 shs

Market Capitalization

$231.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69